The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy

被引:2
|
作者
Nugent, Bethany D. [1 ]
Sereika, Susan M. [1 ]
Rosenzweig, Margaret [1 ]
McCue, Michael [2 ]
Merriman, John D. [1 ]
Bender, Catherine M. [1 ]
机构
[1] Univ Pittsburgh, Sch Nursing, 415 Victoria Bldg,3500 Victoria St, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Sch Hlth & Rehabil Sci, 4028 Forbes Tower, Pittsburgh, PA 15260 USA
关键词
Occupational skill; Employment; Cognitive function; Breast cancer survivors; Anastrozole therapy; WORK; RETURN; DEPRESSION; EMPLOYMENT; ADHERENCE; PATIENT; FATIGUE;
D O I
10.1007/s00520-016-3161-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Previous research has explored occupational activity of breast cancer survivors but has not examined the influence of occupational level on symptoms prospectively. The purpose of this study was to examine the relationship between occupational classification and changes in mood and symptom burden for postmenopausal breast cancer survivors during the first year of anastrozole therapy. This was an exploratory secondary analysis in 49 postmenopausal women receiving anastrozole therapy for early-stage breast cancer. Participants reported their occupation at baseline and completed self-report questionnaires measuring mood and symptom burden at baseline, 6 months, and 12 months. Occupation was classified according to four major skill levels delineated by the International Standard Classification of Occupations (ISCO). Breast cancer survivors employed at occupational skill levels 1 through 3 reported significantly higher depressive symptoms, fatigue, and total symptoms on average than those employed at ISCO skill level 4. After adjusting for multiple comparisons, this pattern remained for the musculoskeletal, vasomotor, and gastrointestinal symptom subscales. Breast cancer survivors employed at lower skill levels (i.e., ISCO 1-3) reported poorer mood and greater symptom burden than breast cancer survivors employed at a higher skill level (i.e., ISCO 4). Assessing baseline occupation of occupationally active breast cancer survivors may improve understanding of the association between types of occupations and mood and symptom trajectories and may inform development of interventions to mitigate symptom severity in order to help breast cancer survivors maintain optimal occupational function and adherence to therapy.
引用
收藏
页码:3401 / 3409
页数:9
相关论文
共 10 条
  • [1] The association between pre-treatment occupational skill level and mood and symptom burden in early-stage, postmenopausal breast cancer survivors during the first year of anastrozole therapy
    Bethany D. Nugent
    Susan M. Sereika
    Margaret Rosenzweig
    Michael McCue
    John D. Merriman
    Catherine M. Bender
    Supportive Care in Cancer, 2016, 24 : 3401 - 3409
  • [2] Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer
    Maura K. McCall
    Susan M. Sereika
    Stephanie Snader
    Alexa Lavanchy
    Margaret Q. Rosenzweig
    Yvette P. Conley
    Jan H. Beumer
    Catherine M. Bender
    Supportive Care in Cancer, 2022, 30 : 9329 - 9340
  • [3] Trajectories of neuropsychological symptom burden in postmenopausal women prescribed anastrozole for early-stage breast cancer
    McCall, Maura K.
    Sereika, Susan M.
    Snader, Stephanie
    Lavanchy, Alexa
    Rosenzweig, Margaret Q.
    Conley, Yvette P.
    Beumer, Jan H.
    Bender, Catherine M.
    SUPPORTIVE CARE IN CANCER, 2022, 30 (11) : 9329 - 9340
  • [4] TRAJECTORIES OF ANASTROZOLE ADHERENCE AND NEUROPSYCHOLOGICAL SYMPTOM BURDEN IN POSTMENOPAUSAL WOMEN WITH EARLY-STAGE BREAST CANCER 18-MONTHS POST-INITIATION OF AROMATASE INHIBITOR THERAPY
    McCall, Maura
    Rosenzweig, Margaret Quinn
    Conley, Yvette
    Beumer, Jan
    Sereika, Susan
    Bender, Catherine
    ONCOLOGY NURSING FORUM, 2023, 50 (02)
  • [5] Patterns of care in early-stage breast cancer survivors in the first year after cessation of active treatment
    Mandelblatt, JS
    Lawrence, WF
    Cullen, J
    Stanton, AL
    Krupnick, JL
    Kwan, L
    Ganz, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 77 - 84
  • [6] The impact of a pre-cancer or current mood disorder on the cognitive functioning of postmenopausal women who receive adjuvant chemotherapy treatment for early-stage breast cancer
    Frosch, Margery
    Tager, Felice A.
    McKinley, Paula
    ANNALS OF BEHAVIORAL MEDICINE, 2008, 35 : S78 - S78
  • [7] Treatment Response Assessment Using Daily Dual-Energy CT during Pre-Operative Radiation Therapy for Early-Stage Breast Cancer
    Noid, G.
    Currey, A. D.
    Tai, A.
    Kelly, T. R.
    Jorns, J.
    Bovi, J. A.
    Kong, A.
    Wadhwa, A.
    Bergom, C.
    Li, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E20 - E21
  • [8] Long-term effect of exemestane therapy on bone mineral density supported by bisphosphonates: Results of 5-year adjuvant treatment in postmenopausal women with early-stage breast cancer
    Hirano, Akira
    Inoue, Hiroaki
    Ogura, Kaoru
    Hattori, Akinori
    Yukawa, Hiroko
    Sakaguchi, Shiho
    Matsuoka, Aya
    Tanaka, Natsuko
    Kodera, Asaka
    Kamimura, Mari
    Naritaka, Yoshihiko
    Shimizu, Tadao
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 (05) : e238 - e242
  • [9] Association between treatment duration and overall survival in early-stage HER2+breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial
    Overkamp, Friedrich
    Moy, Beverly
    Coudert, Bruno
    Wong, Alvin
    Chan, Arlene
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 31 - 31
  • [10] Association between treatment duration and overall survival in early-stage HER2+breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
    Moy, Beverly
    Takahashi, Masato
    Ohtani, Shoichiro
    Chmielowska, Ewa
    Yamamoto, Naohito
    Coudert, Bruno P.
    Xu, Feng
    Wong, Alvin F.
    Chan, Arlene
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)